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It is uncertain whether hypocalcaemia is associated with an increased risk of bleeding. This study 
assessed the dose-related relationship between ionised calcium concentrations and in vitro clot 
strength measured by maximum amplitude (MA) on the thromboelastograph (TEG). 
Methods 
A total of 610 patients who were at risk of bleeding or had active bleeding between 2010 and 2014 
were considered in this retrospective cohort study. A scatter plot with Pearson correlation coefficient 
(r) and multiple linear regression was used to assess the dose-related relationship between ionised 
calcium concentrations and MA on the TEG. 
Results 
The mean ionised calcium of the patients was 1·10 mmol L−1 (interquartile range: 1·04–1·17) and 235 
(38·5%) of them had hypocalcaemia (<1·1 mmol L−1). Hypocalcaemia was more common in patients 
with significant coexisting coagulopathy. Ionised calcium concentrations (r = 0·285, 95% confidence 
interval (CI) 0·211–0·356, P = 0·001), as well as fibrinogen concentrations, platelet counts, 
international normalised ratio (INR) and activated Partial Thromboplastin Time (aPTT), had a 
significant linear correlation with the MA on the TEG. Ionised calcium concentrations and its 
interaction term with platelet count were both significantly associated with the MA on the TEG (slope 
of the regression line 1·1 per 0·1 mmol L−1 increment, 95%CI 0·3 to 1·9, P = 0·011), after adjusting 
for fibrinogen concentrations, platelet counts, INR and aPTT. 
Conclusions 
Ionised calcium concentrations had a concentration-dependent association with in vitro clot strength 
after adjusting for other coagulation abnormalities in patients with coexisting coagulopathy. 
Maintaining a normal ionised calcium concentration, >1 mmol L−1, during critical bleeding is 
recommended. 
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Calcium has a fundamental role as a cofactor in enzymatic reactions, transmembrane ion flux, muscle 
contraction, neuronal activity, coagulation cascade, platelet aggregation, regulation of vasomotor tone 
and cardiac contractility (Kauvar et al., 2006; Lier et al., 2008; Sihler & Napolitano, 2010). 
Hypocalcaemia may occur in patients with substantial amount of bleeding requiring transfusion of 
blood products (Dzik & Kirkley, 1988; British Committee for Standards in Haematology et al., 2006). 
Citrate toxicity has been suggested as the mechanism of hypocalcaemia during massive transfusion 
(Hayes et al., 1980; Dzik & Kirkley, 1988), however, recent evidence suggests that intravenous 
colloid solutions and ischaemia reperfusion can also induce hypocalcaemia and hypocalcaemia-
induced coagulopathy (Vivien et al., 2005). 
Although an in vitro study demonstrated that ionised calcium concentrations >0·56 mmol L−1 would 
be adequate for clot formation in blood donated from healthy volunteers (James & Roche, 2004), 
clinical studies indicate that even mild hypocalcaemia may contribute to a higher risk of bleeding 
requiring multiple transfusions and mortality in patients with critical bleeding (Lier et al., 2008; Ho & 
Leonard, 2011; Magnotti et al., 2011). This discrepancy may due to the fact that the effect of mild 
hypocalcaemia on bleeding may only be apparent in the presence of coexisting coagulopathy. 
The commonly used standard tests of haemostasis, such as International Normalised Ratio (INR), 
activated Partial Thromboplastin Time (aPTT), have had their limitations for many reasons, most 
being time based and failing to give relevant information about the nature and stability of the platelet-
fibrin clot which may be affected by ionised calcium concentrations. 
We hypothesised that hypocalcaemia may have a concentration-dependent effect on in vitro clot 
strength in patients with coexisting coagulopathy and conducted a retrospective cohort study to assess 
whether hypocalcaemia is associated with reduced in vitro clot strength after adjusting for coexisting 
coagulopathy. 
 
MATERIALS AND METHODS 
After obtaining Royal Perth Hospital Ethics Committee approval, we retrieved the data of patients 
who had concurrent thromboelastograph (TEG) and ionised calcium concentration measured between 
January 2010 and March 2014. The TEG test was not a routine coagulation blood test in this study 
centre and was performed only at the time when patients were considered either at risk of bleeding or 
actively bleeding. Patients were considered at risk of bleeding if they required transfusion and with 
abnormal coagulation parameters (INR > 1·5, aPTT > 40 s, fibrinogen <2 g L−1 or platelet count <150 
× 109 L−1). In this study, the patients' platelet count and coagulation blood test results closest to the 
time when TEG was performed were retrieved from a centralised laboratory database. Patients were 
excluded if ionised calcium concentrations were not performed within 4 h prior to the TEG testing. 
All ionised calcium concentrations were measured by an arterial blood gas analyser (ABL800 FLEX, 
Radiometer, Copenhagen, Denmark), and ionised calcium concentrations below 1·1 mmol L−1were 
considered as abnormal and required replacements according to the study centres' massive transfusion 
protocol. All patients included in this study were critically ill patients who were admitted to the 
Intensive Care Unit (ICU) of Royal Perth Hospital. This multidisciplinary ICU admitted over 1500 
critically ill medical and surgical patients per year, including patients with multiple trauma, burns and 
cardiothoracic surgery. Because of the retrospective observational nature of this study, informed 
consent was waived by the ethics committee. 
In this study, in vitro whole blood (without citrate) clot strength was assessed using the maximal 
amplitude (MA) (normal range: 54–72 mm) and angle (normal range: 47–74°) of the TEG (Medtel 
Thromboelastograph, Haemostasis Analyser, Medtel, Lane Cove, New South Wales, Australia). The 
TEG provides a comprehensive evaluation of the overall coagulation function of the whole blood 
sample in vitro and MA on the TEG reflects the strength of the clot during the clotting process 
(Gibbs, 2011). According to the recommendation of the manufacturer of the TEG machine, a MA < 
54 mm or an angle <47° was considered as having a reduced in vitro clot strength. Two channels of 
TEG, one using kaolin alone as activating agent and the other using kaolin with heparinase, were 
conducted for all study patients. All whole blood samples were tested within 4 min of sampling at the 
patient's body temperature. Because some study patients might have received unfractionated heparin 
subcutaneously for venous thromboembolism prophylaxis, TEG data on the MA of the TEG tracing 
from the heparinase channel were used in this study for consistency purpose. 
Statistical analysis 
If we assumed coagulation and calcium concentration results were available in 500 patients and 100 
of them had hypocalcaemia (<1·1 mmol L−1), and a reduced in vitro clot strength was also observed in 
100 patients, this sample size would have >80% power to detect a relative risk difference of >2·0 in 
risk of a reduced in vitro clot strength between patients with and without hypocalcaemia, if the 
incidence of hypocalcaemia among those without reduced in vitro clot strength was 25%. 
The quantitative relationship between ionised calcium concentrations and MA on the TEG was first 
analysed by a scatter plot, using Pearson correlation coefficient (r) to assess the degree of linear 
relationship between these two variables. The relationship between ionised calcium concentrations 
and MA was then further analysed after adjusting for platelet counts, INR, aPTT and fibrinogen 
concentrations in a multiple linear regression. During the modelling process, no variables were 
removed in the multiple linear regression analysis. Because age itself was unlikely to be related to 
the in vitro clot strength, this factor was not analysed in the multivariate linear regression. Transfusion 
requirements and blood pH were not recorded in this dataset, and hence, they were also not analysed 
in the multivariate analysis. 
As a sensitivity analysis, trauma diagnosis and four interaction terms between ionised calcium 
concentrations and platelet count, INR, aPTT or fibrinogen concentration were also entered to the full 
multivariate model to assess whether they would increase the model's predictive ability in terms of 
adjusted coefficient of determination (R2). Insignificant interaction terms (P > 0·05) were then 
removed by a backward stepwise procedure to improve the precision of the final results of this 
sensitivity analysis. A P-value <0·05 was taken as significant in this study, and all analyses were two-
tailed and conducted by spss for Windows (version 22.0, 2014, IBM, Chicago, IL, USA). 
 
RESULTS 
Of the 780 patients who were tested with a TEG during the study period, 610 patients had a 
concomitant ionised calcium concentration measured. The mean ionised calcium of the patients was 
1·10 mmol L−1 (interquartile range: 1·04–1·17) (Fig. 1), and 235 (38 · 5%) of them had 
hypocalcaemia (<1·1 mmol L−1). The distribution of the MA among those with hypocalcaemia is 
described in Fig. 2. The patients with hypocalcaemia were more likely to have cardiac surgery and 
were associated with thrombocytopenia, hypofibrinogenaemia, a prolonged INR or aPTT, and a 
smaller MA on the TEG compared with patients without hypocalcaemia (Table 1). The proportion of 
patients with hypocalcaemia was significantly higher among those with reduced in vitro clot strength 
compared with those without reduced in vitro clot strength (50·4 vs 35·2%, P = 0·002). Likewise, 
moderate hypocalcaemia (<0·9 mmol L−1) (67 vs 19%, P = 0·001) and severe hypocalcaemia (<0·6 
mmol L−1) (100 vs 22%, P = 0·001) were both associated with an increased risk of having reduced in 
vitro clot strength. 
As a continuous predictor, ionised calcium concentrations had a significant correlation with MA on 
the TEG [r = 0·285, 95% confidence interval (CI) 0·211–0·356, P = 0·001] (Fig. 3), with ionised 
calcium <1·0 mmol L−1 appeared to be the likely cut-point for MA to be affected by ionised calcium 
concentrations. Platelet counts (r = 0·495) and fibrinogen concentrations (r = 0·501) were also 
positively associated with the MA on the TEG, whereas INR (r = −0 · 221) and aPTT (r = −0·282) 
were inversely associated with the MA on the TEG. Ionised calcium concentrations remained 
significantly associated with the MA on the TEG, after adjusting for platelet counts, fibrinogen 
concentrations, INR and aPTT (Table 2). The slope of the regression was 1·1 per 0·1 mmol 
L−1 increment in ionised calcium increment and this suggested that for every 0·1 mmol L−1 increment 
in ionised calcium, there was a 1·1 mm increment in MA on the TEG (95% CI: 0·3–1·9) while 
holding platelet count, aPTT, fibrinogen and INR constant. INR was, however, no longer significantly 
associated with the MA on the TEG after adjusting for other covariates. 
The full linear regression model explained about 33·3% of the variability in MA (R2 = 0·333, 
adjusted R2 = 0·314), and the predicted values of MA from the multivariate linear regression were 
associated with the observed values of MA on the TEG in a relatively linear fashion (Fig. 4). Among 
all the predictors assessed, fibrinogen concentrations and platelet counts were more important than 
ionised calcium concentrations, INR and aPTT in explaining the variability of the final multivariate 
model. 
In the sensitivity analysis, the only significant interaction term was between ionised calcium 
concentration and platelet count (with a negative regression coefficient), suggesting that changing 
ionised calcium concentrations would be associated with a larger change in in vitro clot strength in the 
presence of thrombocytopenia. The adjusted R2 of the model was further improved by incorporating 
the interaction term between ionised calcium concentrations and platelet count (0·345 vs 0·326). 
Trauma diagnosis was, however, not significantly associated with an increased risk of reduced in 




This study showed that hypocalcaemia was common in patients with abnormal coagulation 
parameters, and ionised calcium concentrations had a concentration-dependent association with in 
vitro clot strength measured by a TEG in patients who were at risk of bleeding or had active bleeding, 
particularly when there was coexisting thrombocytopenia. These results are clinically relevant and 
require careful consideration. 
First, our results confirmed that hypocalcaemia was common in patients who had critical bleeding and 
coexisting coagulopathy (Lier et al.,2008; Ho & Leonard, 2011). Hypocalcaemia can be induced by 
transfusion of blood products such as fresh frozen plasma as well as intravenous fluid (Vivien et 
al., 2005; Ho & Leonard, 2011; Magnotti et al., 2011), and these therapies can also induce 
haemodilution and coagulopathy at the same time in patients with critical bleeding. As such, it is 
possible that any adverse associations between hypocalcaemia and increased transfusion requirements 
or mortality of patients who have critical bleeding may be purely related to confounding. A previous 
healthy volunteer study inducing hypocalcaemia in normal blood samples in vitro showed that 
hypocalcaemia did not appear to have any apparent effect on the MA of the TEG tracing provided the 
ionised calcium concentrations were above 0·56 mmol L−1 (James & Roche, 2004). This study was, 
however, limited by the use of blood samples without coexisting coagulopathy and, hence, whether 
mild hypocalcaemia may contribute to an increased risk of bleeding in patients with coexisting 
hypocalcaemia and abnormal coagulation parameters remains uncertain. Our results have extended 
the implication of this mechanistic study and showed that even mild hypocalcaemia may have some 
effect on the strength of the clot formation, as measured by the TEG, in patients with coexisting 
coagulopathy. Recent observational studies suggested that hypocalcaemia may be associated with a 
higher risk of intracerebral haemorrhage after thrombolytic therapy (Guo et al., 2015) and a larger 
haematoma volume in haemorrhagic stroke compared with those without hypocalcaemia (Inoue et 
al.,2013). Given previous studies also showed that calcium is an essential cofactor for vitamin K-
dependent coagulation factors (factors II, VII, IX, X) and platelet aggregation, and citrate is a very 
effective regional anticoagulant (Brass et al., 2005; Schilder et al., 2014), our results certainly support 
the current critical bleeding and transfusion guidelines in recommending that ionised calcium 
concentrations should be maintained at a normal range in patients with critical bleeding (British 
Committee for Standards in Haematology et al., 2006; Spahn et al.,2013). 
Second, our results confirmed the increasing recognition of the importance of platelets and fibrinogen 
in the pathogenesis of critical bleeding, haemostasis and thrombosis (Duff et al., 2012; Ho et 
al., 2012; Hagemo et al., 2014). Our multivariate analysis results showed that fibrinogen 
concentrations and platelet counts certainly had a larger effect on in vitro clot strength than 
hypocalcaemia. As such, normalising hypofibrinogenaemia and thrombocytopenia should take a 
higher priority than correcting hypocalcaemia in the management of critical bleeding. These results 
were different from our previous work which showed that hypocalcaemia was more important than 
hypofibrinogenaemia or thrombocytopenia in critial bleeding (Ho & Leonard, 2011). This difference 
could, at least in part, be explained by the use of fresh frozen plasma in patients with more severe 
bleeding and as fresh frozen plasma can also cause hypocalcaemia, this could confound the strength 
of association between mortality and hypocalcaemia. Nevertheless, the sensitivity analysis of this 
study suggested that correcting hypocalcaemia may have a larger effect on improving in vitro clot 
strength in the presence of thrombocytopenia. It is thus prudent to correct both hypocalcaemia and 
thrombocytopenia simultaneously for patients who are actively bleeding. Third, there are also other 
point-of-care whole blood coagulation tests, including ROTEM or the new TEG6s, which can be used 
to assist management of critical bleeding. Because most institutions use citrated blood samples for a 
ROTEM test (or the new TEG6s), any potential adverse effect of hypocalcaemia on in vitro clot 
strength, as demonstrated in this study, would not be apparent if the analysis is conducted on citrated 
blood samples. Ionised calcium concentrations should be measured and hypocalcaemia should be 
excluded when citrated blood samples are used for point-of-care whole blood clotting testing to guide 
transfusion management in critical bleeding. 
Finally, we would like to acknowledge the limitations of this study. Although this study lends 
mechanistic support to the significance of hypocalcaemia in critical bleeding, it is by no means 
definitive. Firstly, some of our patients did not have the ionised calcium concentration and TEG 
measured simultaneously which could have affected the strength as well as accuracy of the 
association between MA on the TEG and ionised calcium concentration. Secondly, because MA was 
primarily used to guide transfusion management, we also did not have data on the fibrinolysis in our 
patients and hence whether fibrinolysis could modify the association between calcium concentrations 
and MA on the TEG remains uncertain. Thirdly, whether maintaining a normal calcium concentration 
in critical bleeding can reduce mortality and other patient-centred outcomes compared with allowing 
mild hypocalcaemia not corrected remains scientifically unproven. An adequately powered 
randomised controlled trial targeting at different ionised calcium concentrations (>0·6, >0·9 or >1·0 
mmol L−1) during critical bleeding is needed to confirm the best way to manage hypocalcaemia in 
patients with critical bleeding. Fourthly, TEG does not assess platelet adhesion function or effect of 
hypothermia on bleeding tendency (Gibbs, 2011). As such, whether hypocalcaemia would have 
substantial concentration-dependent interactions with hypothermia and anti-platelet agents remains 
uncertain. Finally, the size of this study limited the number of variables including higher order 
interaction terms (e.g. INR × platelet count × ionised calcium concentrations or aPTT × platelet count 
× ionised calcium concentrations) we could analyse in the multivariate analysis. 
In summary, hypocalcaemia was common in patients with coagulopathy and at risk of active bleeding. 
Ionised calcium concentrations had a relatively weak but significant concentration-dependent effect 
on in vitro clot strength with and without adjusting for INR, aPTT, platelet count and fibrinogen 
concentration. A change in ionised calcium concentration was associated with a larger change in in 
vitro clot strength in the presence of thrombocytopenia. Our results support the current critical 
bleeding and transfusion guidelines in recommending that ionised calcium concentrations should be 
maintained at a normal range, >1 mmol L−1, in patients with critical bleeding. 
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Figure 2. Histogram showing the distribution of MA on the thromboelastograph for patients with 







Figure 3. Scatter plot showing the relationship between ionised calcium concentrations and MA on 
the thromboelastograph. The horizontal-dotted line defines the lower limit of normal MA (54 mm) 
and the vertical-dotted line defines the ionised calcium = 1·0 mmol L−1 which appears to be the likely 
cut-point for MA to reduce with a reduction in ionised calcium concentrations. The solid line is the 







Figure 4. The relationship between the observed and predicted values of MA on the 













Table 1. Characteristics of the patients with and without hypocalcaemia (≥1·1 mmol L−1) 
 
  With hypocalcaemia (n = 235) 
Without hypocalcaemia 
(n = 375) 
P-value1 
Age, years (IQR)    58 (49–68)    55 (42–70) 0·209 
Male, n (%) 151 (64)  242 (65)  0·999 
Diagnosis, n (%) 
Trauma 22 (9·4) 76 (20·3) 
Cardiac surgery 69 (29·4) 70 (18·7) 
Non-cardiac surgery 23 (9·8) 31 (8·3) 
Sepsis 44 (18·7) 52 (13·9) 
Non-infective medical causes 77 (32·7) 146 (38·8) 
Platelet count (×109 L−1) (IQR)   162 (88–195)    238 (109–268) 0·001 
Fibrinogen concentration, g L−1 (IQR)   3·3 (2·0–4·1)   4·4 (2·5–6·1) 0·009 
INR (IQR)   1·6 (1·3–1·9)    1·4 (1·2–1·6) 0·001 
aPTT, s (IQR)   49 (35–50)    42 (33–46) 0·001 
MA on TEG, mm (IQR)   59 (53–67)    64 (58–72) 0·001 
Abnormal MA, <54mm, n (%) 67 (29)   66 (18) 0·002 
Angle on TEG, degrees (IQR)  60 (53–72)    62 (56–72) 0·215 
Abnormal angle, <470, n (%) 49 (21)   60 (16) 0·158 
CRP, mg L−1 (IQR)*  145 (29–260)   147 (59–200) 0·401 
 
CRP, C-reactive protein; IQR, interquartile range. 
1P-value generated by either χ2 or Mann–Whitney test. 





Table 2. Association between ionised calcium concentrations and MA on the thromboelastograph 
after adjusting for other haematological parameters 
 
Variables Slope of the variable (95% confidence interval) P-value 
Ionised calcium concentration (per 0·1 mmol L−1 increment) 1·1 (0·3 to 1·9) 0·011 
Platelet count (per 10 × 109 L−1 increment) 0·2 (0·13 to 0·24) 0·001 
Fibrinogen concentration (per g L−1 increment) 1·7 (1·2 to 2·3) 0·001 
aPTT (per second increment) −0·1 (−0·05 to −0·14) 0·001 
INR (per unit increment) 0·7 (−1·3 to 2·7) 0·486 
 
Colinearity was not significant between the variables (r < 0·5) and the R2 of the model was 0·333. The 
regression standard error of the regression model was 10·2, suggesting that we can expect the model 
to be accurate in predicting the MA within approximately ±20·4 mm at a 95% confidence level. The 
maximum Cook's distance was 0·08 confirming that there were no outliers or excessive leverage in 
the data points used to generate this model. Residual plot suggested that the zero mean, constant 
variance and independence assumptions for ionised calcium concentrations were met and the QQ plot 
suggested that normality assumption for the regression analysis was met. The adjusted R2 of a reduced 
model by removing one predictor was substantially lower after removing fibrinogen (R2 = 0·254) or 
platelet count (adjusted R2 = 0·272), than ionised calcium (R2 = 0·318), INR (R2 = 0·327) and aPTT 
(R2 = 0·341). 
 
 
 
 
 
 
 
